The role of cyclooxygenase-2 and prostaglandins in colon cancer

Prostaglandins and Other Lipid Mediators

Volumn 82, Issue 1-4, 2007, Pages 147-154

  Eisinger, Annie L ^a,c   Prescott, Stephen M ^a,c   Jones, David A ^a,b,c   Stafforini, Diana M ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Catenin; Adenomatous polyposis coli; Colon cancer; Cyclooxygenase 2; Wnt

Indexed keywords

ACETYLSALICYLIC ACID; AMPHIREGULIN; APC PROTEIN; AXIN; BETA CATENIN; CELECOXIB; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; INDOMETACIN; MATRIX METALLOPROTEINASE; MITOGENIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTANOID; ROFECOXIB; SULINDAC; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR PROMOTER; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; CANCER MODEL; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME INHIBITION; ENZYME REGULATION; ESOPHAGUS CANCER; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; RECTUM CANCER; REGULATORY MECHANISM; RISK REDUCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; STOMACH CANCER;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; BETA CATENIN; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; HUMANS; PROSTAGLANDINS; SIGNAL TRANSDUCTION; UP-REGULATION; WNT PROTEINS;

EID: 33845323045     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2006.05.026     Document Type: Short Survey

References (79)

1. Powell S.M., et al. APC mutations occur early during colorectal tumorigenesis. Nature 359 6392 (1992) 235-237
2. Eberhart C.E., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 4 (1994) 1183-1188
3. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
4. Subbaramaiah K., et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56 19 (1996) 4424-4429
5. Jemal A., et al. Cancer statistics. CA Cancer J Clin 55 1 (2005) 10-30
6. Fodde R., Smits R., and Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1 1 (2001) 55-67
7. Kinzler K.W., and Vogelstein B. Life (and death) in a malignant tumour. Nature 379 6560 (1996) 19-20
8. Lal G., and Gallinger S. Familial adenomatous polyposis. Semin Surg Oncol 18 4 (2000) 314-323
9. Groden J., et al. Identification and characterization of the familial adenomatous polyposis coligene. Cell 66 3 (1991) 589-600
10. Kinzler K.W., et al. Identification of FAP locus genes from chromosome 5q21. Science 253 5020 (1991) 661-665
11. Kargman S.L., et al. Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer. Cancer Res 55 12 (1995) 2556-2559
12. Sano H., et al. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 55 17 (1995) 3785-3789
13. Kutchera W., et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 93 10 (1996) 4816-4820
14. Pugh S., and Thomas G.A. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 35 5 (1994) 675-678
15. Oka M., et al. Prostaglandin E2 levels and lymphocyte subsets in portal venous drainage of colorectal cancers. Am J Surg 167 2 (1994) 264-267
16. Waddell W.R., et al. Sulindac for polyposis of the colon. Am J Surg 157 1 (1989) 175-179
17. Giardiello F.M., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328 18 (1993) 1313-1316
18. Labayle D., et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101 3 (1991) 635-639
19. Nugent K.P., et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80 12 (1993) 1618-1619
20. Thun M.J., et al. Aspirin use and risk of fatal cancer. Cancer Res 53 6 (1993) 1322-1327
21. Thun M.J., Namboodiri M.M., and Heath Jr. C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325 23 (1991) 1593-1596
22. Steinbach G., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 26 (2000) 1946-1952
23. Su L.K., et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256 5057 (1992) 668-670
24. Boolbol S.K., et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56 11 (1996) 2556-2560
25. Chiu C.H., McEntee M.F., and Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 57 19 (1997) 4267-4273
26. DuBois R.N., Giardiello F.M., and Smalley W.E. Non-steroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 25 4 (1996) 773-791
27. Singh J., Hamid R., and Reddy B.S. Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon car cinogenesis. Cancer Res 57 16 (1997) 3465-3470
28. Pereira M.A., et al. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15 5 (1994) 1049-1054
29. Samaha H.S., et al. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 57 7 (1997) 1301-1305
30. Reddy B.S., et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60 2 (2000) 293-297
31. Oshima M., et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 92 10 (1995) 4482-4486
32. Oshima M., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 5 (1996) 803-809
33. Oshima M., et al. Chemoprevention of intestinal polyposis in the Apcdelta7 16 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61 4 (2001) 1733-1740
34. Rubinfeld B., et al. Association of the APC gene product with beta-catenin. Science 262 5140 (1993) 1731-1734
35. Su L.K., Vogelstein B., and Kinzler K.W. Association of the APC tumor suppressor protein with catenins. Science 262 5140 (1993) 1734-1737
36. Behrens J., et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3 beta. Science 280 5363 (1998) 596-599
37. Fagotto F., et al. Domains of axin involved in protein-protein interactions, Wnt pathway inhibition, and intracellular localization. J Cell Biol 145 4 (1999) 741-756
38. Hart M.J., et al. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 8 10 (1998) 573-581
39. Kishida S., et al. DIXdomains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol 19 6 (1999) 4414-4422
40. Rubinfeld B., Tice D.A., and Polakis P. Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1 epsilon. J Biol Chem 276 42 (2001) 39037-39045
41. Ikeda S., et al. GSK-3 beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene 19 4 (2000) 537-545
42. Marikawa Y., and Elinson R.P. beta-TrCP is a negative regulator of Wnt/beta- catenin signaling pathway and dorsal axis formation in Xenopus embryos. Mech Dev 77 1 (1998) 75-80
43. Aberle H., et al. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16 13 (1997) 3797-3804
44. Reguart N., et al. The role of Wnt signaling in cancer and stem cells. Fut Oncol 1 6 (2005) 787-797
45. Reya T., et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423 6938 (2003) 409-414
46. Nagase H., and Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 2 6 (1993) 425-434
47. Smits R., et al. Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development. Genes Dev 13 10 (1999) 1309-1321
48. Kawahara K., et al. Down-regulation of beta-catenin by the colorectal tumor suppressor APC requires association with Axin and beta-catenin. J Biol Chem 275 12 (2000) 8369-8374
49. von Kries J.P., et al. Hot spots in beta-catenin for interactions with LEF-1, conductin and APC. Nat Struct Biol 7 9 (2000) 800-807
50. Morin P.J., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275 5307 (1997) 1787-1790
51. Satoh S., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of Axin 1. Nat Genet 24 3 (2000) 245-250
52. Hsi L.C., Angerman-Stewart J., and Eling T.E. Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. Carcinogenesis 20 11 (1999) 2045-2049
53. Mei J.M., et al. Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated beta-catenin-LEF-1 transcription complex in mouse colonic epithelial cells contrasting in Apc. Carcinogenesis 20 4 (1999) 737-740
54. Araki Y., et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63 3 (2003) 728-734
55. He T.C., et al. Identification of c-MYC as a target of the APC pathway. Science 281 5382 (1998) 1509-1512
56. Howe L.R., et al. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformedmouse mammary epithelial cells. Cancer Res 59 7 (1999) 1572-1577
57. Haertel-Wiesmann M., et al. Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells. J Biol Chem 275 41 (2000) 32046-32051
58. Goodwin J.S., and Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 3 4 (1983) 295-315
59. Sheng H., et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58 2 (1998) 362-366
60. Sheng H., et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276 21 (2001) 18075-18081
61. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase 2. Cell 83 3 (1995) 493-501
62. Goodwin J.S., Bankhurst A.D., and Messner R.P. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med 146 6 (1977) 1719-1734
63. Balch C.M., et al. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95 1 (1984) 71-77
64. Huang M., et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58 6 (1998) 1208-1216
65. Stolina M., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164 1 (2000) 361-370
66. 2 in Apc (Delta 716) knockout mice. Nat Med 7 9 (2001) 1048-1051
67. 1 in colon carcinogenesis. Cancer Res 59 20 (1999) 5093-5096
68. Mutoh M., et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 62 1 (2002) 28-32
69. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 12 (1996) 5739-5742
70. Pai R., et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 3 (2002) 289-293
71. Shao J., et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63 17 (2003) 5218-5223
72. Buchanan F.G., et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278 37 (2003) 35451-35457
73. Castellone M.D., et al. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310 5753 (2005) 1504-1510
74. 4 prostanoidreceptors by prostaglandin E2. J Biol Chem 277 4 (2002) 2614-2619
75. Shao J., et al. Prostaglandin E2 stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 280 28 (2005) 26565-26572
76. McEntee M.F., Chiu C.H., and Whelan J. Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20 4 (1999) 635-640
77. Orner G.A., et al. Suppression of tumor igene sis in the Apc (min) mouse: down- regulation of beta-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 24 2 (2003) 263-267
78. Hawcroft G., et al. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23 1 (2002) 107-114
79. Koornstra J.J., et al. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary non-polyposis color ectal cancer and familial adenomatouspolyposispatients. Cancer Epidemiol Biomark Prev 14 7 (2005) 1608-1612